Belgium's Devgen spins off new company with kinase inhibitor assets
This article was originally published in Scrip
Devgen has spun off certain assets and intellectual property from its former pharma division into a new company called Amakem. The start-up received €1.5 million in seed financing from LRM (a Flemish investment company), Life Sciences Research Partners (LSRP; a non-profit Belgium organisation focused on supporting the innovation) and VINNOF (a Flemish innovation fund).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.